AI in Trial Eligibility Screening Market Size, Share & Industry Analysis, By Component (Software/Platforms and Services), By Deployment (Cloud-Based, On-Premise, and Hybrid), By Technology (NLP, Machine Learning & Deep Learning, and Generative AI/LLMs), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Function (Protocol Criteria Extraction, Patient-Trial Matching, and EHR/EMR Screening Automation), By Therapeutic Area (Oncology, Rare Diseases, and Neurology), By End User (Pharmaceutical & Biotech Companies, CROs, and Hospitals & Trial Sites), and Regional Forecast, 2026-2034

The global AI in trial eligibility screening market was valued at USD 0.65 billion in 2025. The market is projected to grow from USD 0.81 billion in 2026 to USD 4.80 billion by 2034, exhibiting a CAGR of 24.9% during the forecast period.

The global market is emerging as a high-growth area within clinical trial technology. As clinical trial protocols become more complex, especially in oncology, rare diseases, neurology, and precision medicine, manual screening often leads to delays, missed patients, and higher recruitment costs. AI-enabled eligibility screening tools address this challenge by analysing EHR data, clinical notes, lab results, genomic information, and protocol criteria to improve patient-trial matching. This is encouraging life sciences companies and healthcare providers to invest in automated screening, workflow integration, and AI-driven recruitment solutions to accelerate enrolment and improve trial performance.

• For instance, in August 2025, the Cleveland Clinic launched Dyania Health’s Synapsis AI platform across its health system to accelerate clinical trial The platform uses medically trained large language models to interpret clinical notes, medical records, imaging, pathology, organ function, and age-related information, helping improve patient identification for complex conditions and reduce manual screening burden.

Furthermore, new product launches, increasing EHR integration, strategic partnerships, and new product launches by key operating companies strengthen their market position and support overall market growth.

AI in Trial Eligibility Screening Market Driver

Rising Trial Enrollment Delays to Drive Product Adoption

Clinical trial enrollment delays are becoming a major driver for the market. Sponsors and CROs continue to lose time when eligible patients are not identified quickly enough. As trial protocols become more complex, site teams spend more effort reviewing medical records, lab values, diagnosis history, and inclusion/exclusion criteria manually. This slows recruitment, increases trial operating costs, and can delay drug development timelines. As a result, companies are adopting AI-based eligibility screening platforms that can analyze patient data faster, identify qualified participants earlier, and reduce the manual burden on research staff.

• For instance, in September 2025, Tribally secured USD 4.7 million in funding and launched Margo, its agentic AI solution that multiplies trial enrollment by converting patient matches into participants. The development aimed to solve clinical trial recruitment bottlenecks by matching, engaging, and enrolling patients in clinical trials.

Download Free sample to learn more about this report.

In June 2026, the WHO reported that there was a steady rise in the number of newly recruiting trials registered on ICTRP for most WHO regions, peaking in 2021, and again in 2024. The number of trials registered in the WHO’s Western Pacific and South-East Asia regions has increased at a much higher rate than in other regions. For example, in 2025, the number of trials registered in the Western Pacific was 31,097, i.e., more than 30 times higher than that in Africa. Such increasing volumes of clinical trials in emerging economies is likely to support the global market growth.

AI in Trial Eligibility Screening Market Restraint

Data Privacy, EHR Integration Barriers, and Validation Concerns May Restrain Market Adoption

The market growth is restrained as AI-based trial eligibility screening depends on access to sensitive patient records, including physician notes, lab results, imaging reports, genomic data, and diagnosis history. Many hospitals and trial sites are cautious about sharing this data because privacy rules, consent requirements, cybersecurity risks, and cross-border data regulations can slow platform deployment. At the same time, AI screening tools must be validated carefully given that incorrect eligibility decisions can lead to missed patients, unsuitable referrals, protocol deviations, or additional review burden for research coordinators. As a result, adoption can be slower in smaller hospitals, highly regulated regions, and sites with fragmented EHR systems, even when sponsors see strong value in automation.

• For instance, in September 2025, myTomorrows stated in a company press release that clinical trial recruitment remains challenging given that phase III trials average 13–18 months, 37% of sites under-enroll, one-third enroll no patients, and 72% of physicians consider search and pre-screening too time-consuming. This highlights that even with AI-enabled recruitment tools, fragmented referral workflows and high site burden continue to restrain faster adoption of eligibility screening platforms.

AI in Trial Eligibility Screening Market Opportunity

Expanding Use of Generative AI in Protocol Interpretation to Open New Commercial Opportunities

Generative AI is creating strong growth opportunities for market players as clinical trial protocols are becoming longer, more complex, and harder for site teams to review manually. Many eligibility criteria depend on unstructured information such as physician notes, pathology reports, medication history, imaging summaries, and prior treatment details. As a result, traditional keyword-based screening often misses suitable patients or creates additional manual review work. Generative AI and LLM-based tools can interpret protocol language, extract inclusion and exclusion criteria, compare them with patient records, and provide criterion-level explanations for coordinator review. This creates an opportunity for vendors to offer more advanced screening platforms that improve trial matching accuracy, reduce site workload, and support faster enrollment for complex studies.

• For instance, in December 2025, Mass General Brigham launched AIwithCare, a new company built around a software platform that uses generative AI to screen patients for clinical trial eligibility. The platform included RECTIFIER, a RAG-enabled clinical trial infrastructure tool that reviews EHR data such as diagnoses, key health indicators, medications, clinical notes, and reports to determine eligibility and support faster patient recruitment.

Segmentation

Key Insights

The report covers the following key insights:

• Overview of Technological Advancements in AI-enabled Trial Eligibility Screening
• Overview of Commercial Impact on Trial Cost, Timelines, and Enrollment Efficiency
• Regulatory Scenario, By Key Countries/Regions
• New Product Launches, By Key Players
• Key Industry Developments (Strategic Partnerships, Acquisitions, and Mergers)
• Key Startups, By Key Regions

Analysis by Component

Based on component, the global AI in trial eligibility screening market is segmented into software/platforms and services.

The software/platforms segment held the largest share in the AI in trial eligibility screening market. AI-based eligibility screening is mainly delivered through digital platforms that extract protocol criteria, read clinical data, match patients to trials, and support recruitment workflows. Sponsors, CROs, and trial sites prefer software-led solutions as they can be scaled across multiple studies, integrated with EHR systems, and updated as protocols change. As a result, software/platforms capture the larger share of the market compared with services.

• For instance, in February 2025, Inovalon launched Clinical Research, Patient Finder. This AI-enabled solution automatically scans EHRs and continuously matches eligible patients with trials based on study-specific inclusion and exclusion criteria. The development supports the dominance of software/platforms given that the core value is delivered through automated patient identification and digital screening workflows.

Analysis by Deployment

Based on deployment, the market is segmented into cloud-based, on-premises, and hybrid.

The cloud-based segment is likely to dominate the market. Cloud platforms make it easier to update trial criteria, manage multi-site workflows, run analytics at scale, and support remote access for distributed study teams. Since many emerging AI vendors are offering SaaS-based platforms, customers can deploy solutions faster without heavy on-premise infrastructure.

• For instance, in December 2025, Anova launched a free AI-enabled clinical trial patient matching solution within the AnovaOS platform, connecting patients to more than 200,000 open clinical trials and supporting automated screening across a global just-in-time research network. This highlights how cloud/network-based models can expand access and scale trial matching beyond individual sites.

Analysis by Technology

Based on technology, the market is segmented into Natural Language Processing (NLP), machine learning & deep learning, generative AI / Large Language Models (LLMs), computer vision / OCR-based document intelligence, and others.

The Natural Language Processing (NLP) segment is anticipated to dominate the AI in trial eligibility screening market. Most eligibility-relevant information is stored in unstructured formats such as physician notes, pathology reports, radiology summaries, medication history, and protocol text, which is a key factor pushing the dominance of this segment. Trial teams cannot depend only on structured EHR fields as many inclusion and exclusion criteria require clinical interpretation. NLP helps convert this unstructured information into searchable data, which improves patient identification and reduces manual chart review.

• For instance, in October 2025, Triomics announced that a leading global cancer center would integrate its AI-powered clinical trial matching and screening platform. The platform parses patient records and surfaces eligible trials with itemized, criterion-by-criterion rationale and source citations, directly supporting NLP-led screening of complex clinical records.

Analysis by Phase

Based on phase, the market is segmented into phase I, phase II, phase III, and phase IV.

The Phase III segment is likely to dominate due to these trials. They usually require larger patient populations, more sites, broader recruitment geographies, and strict enrollment timelines. As patient volumes increase, manual eligibility screening becomes more expensive and difficult for study teams to manage. Sponsors, therefore, use AI screening tools to reduce screen failures, improve site productivity, and identify eligible patients faster across large trial networks. Further, it generates stronger commercial demand given that enrollment delays can significantly affect launch timelines and development costs.

• For instance, in June 2025, IQVIA launched new AI agents for life sciences and healthcare, stating that healthcare-specific AI applications would help enhance and streamline clinical trials with workflow coordination and insights. These instances support Phase III dominance.

Analysis by Function

Based on function, the market is segmented into protocol criteria extraction, patient-trial matching, EHR/EMR screening automation, referral workflow automation, and others.

The patient-trial matching segment is likely to capture the largest share in the market. It is the central commercial use case of AI eligibility screening. Sponsors and trial sites primarily adopt these tools to find eligible patients faster, reduce missed enrollment opportunities, and improve recruitment conversion. As a result, vendors that can combine clinical data, eligibility logic, biomarker information, and referral workflows are better positioned to capture a larger revenue share.

• For instance, in April 2026, Massive Bio announced the publication of a prospective study showing that its neuro-symbolic, multi-agent AI platform matched cancer patients to clinical trials four times faster than conventional methods across 3,804 cancer patients. Such instances highlight why patient-trial matching remains the most commercially important function in the market.

Analysis by Integration Model

Based on integration model, the market is segmented into standalone and integrated.

The integrated solutions segment is poised for growth over the upcoming years. Eligibility screening becomes more useful when it is connected directly with EHR systems, pathology systems, clinical trial management workflows, and site referral processes. Integrated platforms reduce this friction to manually upload or enter patient information by continuously scanning clinical records and surfacing eligible patients inside existing workflows. This improves adoption among hospitals and trial sites as research teams can screen patients without adding a major administrative burden.

• For instance, in June 2026, Nexentis Technologies Inc. collaborated with Boltz, PBC. This AI research lab focuses on biomolecular foundation models and drug discovery workflows to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins of interest to the company’s pipeline.

Analysis by Therapeutic Area

Based on therapeutic area, the market is segmented into oncology, rare diseases, neurology, immunology/inflammation, and others.

The oncology segment is likely to dominate the AI in trial eligibility screening market as cancer trials often have the most complex eligibility criteria, including tumor type, stage, mutation status, prior therapies, biomarker results, lab values, and performance status. These requirements make manual screening slow and increase the risk of missing suitable patients. AI eligibility platforms are especially valuable in oncology given that they can read large clinical records, interpret biomarker-driven criteria, and match patients to precision medicine trials. As oncology also represents one of the largest areas of clinical trial activity, it creates a stronger demand for AI-based trial matching compared with many other therapeutic areas.

• For instance, in 2025, Memorial Sloan Kettering Cancer Center (MSK) collaborated with Triomics, an oncology-focused generative AI company, to deploy the company’s AI-powered clinical trial matching and screening platform in MSK’s active clinical trials.

Analysis by End User

Based on end user, the market is segmented into pharmaceutical & biotech companies, CROs, hospitals & trial sites, academic medical centers, and others.

The pharmaceutical and biotech companies segment is anticipated to account for a dominant share in the market. The strongest financial incentive to reduce enrollment delays is a key factor impelling segment growth. Their investment in AI eligibility screening to improve feasibility planning, identify eligible populations, and support the growth of the segment. Key players operating in the market are actively focusing on new product launches and supporting global market growth.

• For instance, in May 2025, Medidata launched Medidata Protocol Optimization, an AI-enabled solution designed to improve protocol design, reduce patient and site burden, accelerate recruitment, and increase clinical trial efficiencies.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of region, the market has been analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 50.0% of the global AI in trial eligibility screening market in 2025. The region dominates owing to the presence of a large clinical trial base, advanced hospital networks, strong EHR adoption, and high spending by pharmaceutical and biotechnology companies. Clinical research sites in the region manage large patient volumes. As a result, hospitals and sponsors are adopting AI-based screening platforms to reduce coordinator workload, improve trial access, and identify eligible patients earlier in the care journey, encouraging strategic partnerships among key operating players.

• For instance, in May 2026, Advocate Health partnered with Lind to help connect more cancer patients to potentially life-saving clinical trials. The platform will be embedded into the EHR and will automatically screen patients for cancer clinical trials, while keeping clinician oversight before enrollment. Advocate Health stated that manual screening is laborious and difficult to scale and Lind’s AI-enabled screening could reduce eligibility assessment time from up to an hour per patient to minutes.

The Europe market is expected to grow at a significant CAGR during the forecast period. Healthcare systems across the region are trying to improve patient access to clinical trials while managing fragmented data, multilingual medical records, and strict privacy requirements. This creates demand for AI tools that can interpret large volumes of trial data in local-language records, extract eligibility evidence, and support privacy-conscious patient matching.

• For instance, in March 2026, myTomorrows partnered with Clínica Universidad de Navarra (CUN), a non-public academic hospital affiliated with the University of Navarra. Through this collaboration, CUN introduced AI-assisted patient trial matching, integrated within its electronic health record (EHR) and operating as part of its controlled clinical environment.

The Asia Pacific market is expected to grow at a stable CAGR during the forecast period. Asia Pacific is becoming a significant destination for multinational clinical trials due to its large patient pool, rising oncology and rare disease burden, expanding hospital networks, and increasing investment in precision medicine. This is creating a strong growth opportunity in countries such as Taiwan, Japan, South Korea, Singapore, Australia, China, and India, where sponsors are seeking faster and more targeted enrollment pathways. Strategic collaborations among key companies are being witnessed to bring forth innovative offerings in the market. 

• For instance, in May 2026, Precision Medicine Asia Limited collaborated with Lind to expand AI-powered clinical trial screening across the Asia Pacific. The joint venture combined the company’s regional clinical-genomic infrastructure with Lind’s evidence-driven AI platform to accelerate patient identification for multinational trials, supporting stronger adoption of AI-enabled eligibility screening in the region.

Key Players covered

The global AI in trial eligibility screening market is moderately fragmented but increasingly consolidating.

The report includes the profiles of the following key players.

• Tempus AI, Inc. (U.S.)
• TriNetX, LLC (U.S.)
• IQVIA Inc. (U.S.)
• Medidata Solutions, Inc. (U.S.)
• Komodo Health, Inc. (U.S.)
• Trialbee AB (Sweden)
• Massive Bio, Inc. (U.S.)
• myTomorrows (Netherlands)
• Antidote Technologies Ltd. (U.K.)
• TrialX, Inc. (U.S.)

Key Industry Developments

• May 2026: SEQSTER PDM, Inc. launched 1-Click Eligibility, an AI solution that helps research teams identify eligible clinical trial participants in a very short period of time. Many early deployments have already accelerated drug development timelines.
• May 2026: Azra AI launched its Agentic AI Clinical Research Platform. The platform introduced a Unified Patient Intelligence Layer that harmonizes fragmented EHR data to power the entire clinical trial lifecycle.